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ABSTRACT 
 The set of host- and pathogen-specific molecular features of a disease comprise its 
“signature”.  We hypothesize that biological signatures enables distinctions between 
vaccinated vs. infected individuals. In our research, using porcine samples, protocols were 
developed that could also be used to identify biological signatures of human disease.   
Different classes of molecular features will be tested during this project, including 
indicators of basic immune capacity, which are being studied at this instance.    
 These indicators of basic immune response such as porcine cytokines and 
antibodies were validated using Enzyme-linked immunosorbent assay (ELISA).  This is an 
established method that detects antigens by their interaction with a specific antibody 
coupled to a polystyrene substrate.  Serum from naïve and vaccinated pigs was tested for 
the presence of cytokines. We were able to differentiate the presence of porcine IL-6 in 
normal porcine serum with or without added porcine IL-6 by ELISA.  In addition, four 
different cytokines were spotted on a grating-coupled surface plasmon resonance imaging 
system (GCSPRI) chip and antibody specific for IL-8 was run over the chip.  Only the 
presence of IL-8 was detected; therefore, there was no cross-reactivity in this combination 
of antigens and antibodies.  This system uses a multiplexed sensor chip to identify 
components of a sample run over it.  The detection is accomplished by the change in 
refractive index caused by the interaction between the antibody spotted on the sensor chip 
and the antigen present in the sample.   
 As the multiplexed GCSPRI is developed, we will need to optimize both sensitivity 
and specificity, minimizing the potential for cross-reactivity between individual analytes.  
The next step in this project is to increase the sensitivity of detection of the analytes.  
Currently, we are using two different antibodies (that recognize a different part of the 
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antigen) to amplify the signal emitted by the interaction of antibody with its cognate 
antigen.   
 The development of this sensor chip would not only allow to detect FMD virus, but 
also to differentiate between infected and vaccinated individuals, on location.  
Furthermore, the diagnosis of other diseases could be done with increased accuracy, and in 
less time due to the microarray approach. 
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INTRODUCTION 
 Currently, the diagnosis of infectious diseases is often limited to the identification 
of the causative pathogen.  We hypothesize that the molecular characteristics of the host 
response produced as a result of an infection will provide an improved tool for its 
diagnosis, and will also lead to better therapeutic managements of these diseases.  The set 
of host- and pathogen-specific molecular features of a disease comprise its “signature”.  
For example, a breast cancer signature has recently been developed.  The results of the 
study show that the signature was more accurate in selecting the patients assigned to good 
versus poor prognosis groups.  For instance, while using the traditional methods based on 
histological as well as clinical characteristics, only between 7 and 15% of patients were 
assigned to the good prognosis group; 40% of them were assigned to the same group 
according to the signature approach.  Follow up showed that the patients in the good 
prognosis group, according to the signature, were less likely to develop metastasis [1].     
 We are employing Grating-coupled Surface Plasmon Resonance Imaging 
(GCSPRI), an instrument that allows for the simultaneous detection of different analytes 
from the same sample (including proteins, DNA, cells, bacteria and viruses) using the 
same chip.   The GCSPRI instrument uses changes in the refractive index caused by 
analyte capture by the sensor chip to identify the presence of the analyte. 
 Traditional Surface Plasmon resonance (SPR) measures the interaction of an 
antibody-antigen pair by detecting changes in the refractive index of an aqueous medium 
near a metal surface [2].  In order for the resonance (plasmon) to occur certain conditions 
such as wavelength and angle of incidence have to be met.  The Kretschmann 
configuration (Figure 1) uses a prism, which has a high index of refraction to produce the 
necessary conditions for the surface plasmon to occur.  The GCSPRI technology uses a 
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sensor chip that contains a grating on the surface that allows for the deflection of light at 
different angles (Figure 2).  When the velocity and momentum of some of these waves 
coincide with the ones of the plasmon, electrons on the surface of the chip are coupled 
forming a surface plasmon [2].  Therefore, there is a need to use a prism or two different 
mediums such as liquid and metal surface to create the resonance and detect the 
interaction.   
 
 
Figure 1. Kretschmann prism configuration [3]            Figure 2. Grating-coupled chip configuration [3]                                                          
                                              
 
 Our work is concerned with the identification of a biological signature that will 
enable the distinction between vaccinated vs. infected hosts. This signature comprises 
pathogen-and host-specific molecular features that are specific for Foot-and-mouth 
disease.  Using only one marker, such as the concentration of antibodies against Foot and 
Mouth disease virus present in serum, would not be sufficient to make this distinction.  In 
order for the vaccine to work, the antigen introduced to the body would have to be a part 
or an inactivated form of the virus.  Therefore, the distinction between the antibodies 
against a live or inactivated virus would be very difficult to make since both would have 
the same components.  Even if this distinction could be made, the concentration of 
antibodies or the virus could vary among individuals.  Therefore, besides looking at one or 
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two features, the animal's immune response would be tested in order to make that 
distinction.  This signature approach would make a more accurate detection of infection 
because there would be dozens of features tested and evaluated statistically. 
 The research is being done using porcine samples, but the same protocols could be 
used to develop biological signatures of human disease. There are four classes of 
molecular features to be tested:  (1) indicators of basic immune capacity (antibody levels, 
levels of cytokines (“immune hormones”), and numbers of immune cell subpopulations), 
(2) indicators of specific immune response (antibodies specific for the different viruses or 
bacteria tested), (3) indicators of tissue damage or cellular stress (heat shock proteins and 
metallothionein), and (4) indicators of autoimmunity (presence of antibodies against host 
cellular components). 
 Our project looks for differences in molecular features of cattle infected with or 
vaccinated against Foot-and-mouth disease virus.  FMD is caused by a single-stranded, 
plus-sense RNA virus.  It has several serotypes that have been found in different parts of 
the world, and they include A, O, C, Asia1, and South African Territories 1, 2, and 3 [4].  
This disease does not have a high mortality rate, however, it severely decreases the 
animal's productivity, and since it spreads fairly easily, all animals part of the herd need to 
be killed.  Furthermore, infected animals cannot be sold internationally, and vaccination 
limits the market for cattle due to the difficult differentiation between infected and 
immunized groups.  Also, if the inactivated virus used in vaccines is not fully inactivated it 
could cause the transformation of the virus to the wild type causing infections [5].  
Therefore, the financial burden for the owners of infected herds is very high. The last 
major out-break of FMD happened in Great Britain in 2001, and it caused the loss of 
thousands of cattle world-wide along with its financial consequences.  There is a need for 
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developing an assay that could rapidly and accurately detect the presence of this virus.  
This way the infected animals could be isolated preventing the spread of the disease.  
Since some of the FMD symptoms are similar to other diseases such as vesicular 
stomatitis, it is necessary to have the ability to test specifically for the presence of FMDV.  
One of the challenges of this project is that no laboratory in the continental United States 
is allowed to have the virus.  We are currently working with pigs vaccinated with a 
synthetic protein of the virus.  
 Designing an assay to test a specific signature has some added challenges.  For 
instance, all the animals in the herd have different genetic characteristics, and will react to 
an infection in a different way.  Even if they are infected by the same virus at the same 
time, their immune systems might react differently depending on each individual's health. 
Polymorphisms in cytokine genes might cause individuals to have different concentrations 
of cytokines at any given time.  Also, mutations in the genes that code for the receptors of 
B and T lymphocytes might cause them react differently when a pathogen infects the 
body.   Therefore, the parameters of the signature have to be carefully studied to minimize 
the errors.  
   We are searching for statistically significant differences in the serum levels of 
analytes that would allow us to differentiate between infected versus vaccinated 
individuals.  Table 1 shows some examples of how cytokines vary according to the 
individual's circumstances. Our initial studies addressed how specific the interactions 
between antigen and antibody are, and what are the limits in the detection of each analyte.  
One of the pitfalls is that porcine antibodies have not been previously adsorbed; therefore, 
they might interact non-specifically with other serum components.  Also, when running 
the different antibodies sequentially in GCSPRI, some might interact with more than one 
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analyte.  As a consequence, it will be difficult to determine the concentration of each 
antigen in serum once all the analytes are spotted on the chip.  In order to decrease the 
cross-reactivity issues, we will use antibody pairs.  In this way each component of the pair 
will recognize a different part (epitope) of the same analyte (Figure 3).   The first antibody 
will be adsorbed to the matrix of the plate.  Then, the antigen (in serum) would be allowed 
to bind.  The second antibody, which would be coupled to an enzyme, would bind to a 
different part of the antigen.  Each step will be followed by washing (as explained in the 
ELISA protocol) to eliminate the unbound molecules.  Then, the substrate for the coupled 
enzyme would be added; and this reaction would produce color.  The change in color 
would be representative of the amount of antigen captured by the first antibody and bound 
to the second one.    
 
 
Table 1. Concentration of IL-2, IL-6, IL-8, and TNFa in the serum of smokers and non-
smokers suffering from schizophrenia (ng/ml) [6].  This table shows an example of a 
signature (neither schizophrenia nor smoking are related to our project). 
 Smokers Non-smokers 
IL-2 4.1±2.3 7.6±7.4 
IL-6 0.34±0.11 0.41±0.10 
IL-8 0.98±0.30 1.1±0.28 
TNFa 10.1±1.8 10.7±2.7 
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1: Antigen Capture    2: Matched Pair      3: Enzyme Conversion 
                                  Antibody-Enzyme       of Substrate to  
                                  Conjugate binding      Colored Product 
 
Figure 3.  Diagram of sandwich ELISA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Colored Substrate 
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MATERIALS AND METHODS 
Reagents 
Recombinant porcine TNFα, IL-4, INFγ, IL-10, IL-2, IL-1β, IL-6, IL-8 mouse anti-porcine 
IL-4, mouse anti-porcine INFγ, were purchased from Cell Sciences (Canton, MA).  Mouse 
anti porcine TNFα, native porcine IgM, mouse anti-porcine IgM were purchased from 
AbD Serotec (Raleigh, NC).  Mouse anti-porcine IL-10, mouse anti-porcine IL-2 were 
purchased from R&D Systems (Minneapolis, MN).  Mouse anti-porcine IL-1β, mouse 
anti-porcine IL-6, mouse anti-porcine IL-8, recombinant porcine IL-12 p70, mouse anti-
porcine IL-12 p70 were purchased from Pierce Endogen (Rockford, IL).  Porcine IgG was 
obtained from Bethyl Laboratories, Inc (Montgomery, TX). Rabbit anti-mouse IgG-AP 
conjugated was purchased from Fisher Scientific (Pittsburg, PA). 
 
Enzyme linked immunosorbent assay (ELISA).  
96-well 2 HB Immulon plates (Thermo Labsystems, Franklin, MA) were coated with 
antigens or antibodies depending on the assay. After the plates were incubated for 1 hour 
at 37ºC, they were washed three times with PBST (137 mM NaCl, 2.6 mM KCL,1.6mM 
Kh2PO4, 1mM Na2HPO4,0.05% Tween 20 and 0.2% NaN3 , pH 7.2) in an automated 
plate washer (Biotek, Burlington, VT).  Then, each well was blocked with 200 µl of 2% 
BSA in PBST for 1 hour at 37ºC.  The plates were washed again, and coated with 100 µl 
of the corresponding antigen or antibody. The plates were incubated for 1 hour at 37ºC, 
and washed.  Then, 100µl of a 1:2000 dilution of rabbit-anti-mouse-IgG coupled with 
Alkaline Phosphatase was added to each well.  Again the plates were incubated for 1 hour 
at 37ºC, and washed for the last time.  Finally, each well was coated with 100 µl of p-
Nitrophenyl Phosphate, Disodium salt (PNPP, Sigma-Aldrich, St Louis, MO) in substrate 
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buffer (1mg/ml). The change in color was measured in a plate reader (Molecular Devices, 
Menlo Park, CA) at 405 nm for 10 minutes. 
 
 Microarray preparation 
The GCSPR chips were washed with 70% ethanol and rinsed with distilled water to 
remove any possible contamination. The chips were air-dried and printed using the 
MicroCASTer Pin System (Schleicher & Schuell Inc.).  The different porcine antigens, 
and control molecules (BSA) were each spotted on the gold surface of the chip (50 
nL/spot) at different concentrations.  The chips were then incubated for 1 hour in a 
humidified, 37°C incubator to allow for protein adsorption to the gold surface. After the 
chips were removed from the incubator, they were placed in a dessicator at 4°C overnight, 
before use in the GCSPR instrument. 
 
 
GCSPR assay 
Once installed in the GCSPR instrument’s flow cell, the chips were blocked with 2% BSA 
in PBS (3x5ml flushes followed by 5 min incubations).  Then they were washed with PBS 
(20 min at 250 µl/min) and angle scans were done in order to measure the initial baseline 
GCSPR angle. Sequential angle scans that measure GCSPR angle shifts were performed 
throughout the experiment.  The different analytes were passed across the sensor chip 
surface for 30 min at 100 µl/min, after a PBS run of 10 min at 100 µl/min.  The same PBS 
run was done in between the analyte runs. 
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RESULTS 
The available porcine cytokines were validated using ELISA.  The detection of each 
cytokine, which was plated at a concentration of 25ug/ml, ranges from 4.48 to 259.33 
mDeg/min. This variation could be due to the different sizes of the cytokines, and the 
specificity of the antibodies used. Most of the validation experiments were duplicated with 
comparable results.  
 
 
Figure 4.  Porcine cytokine validation by ELISA.  Procedure:  PBS was added to the 
samples to achieve a concentration of 25ug/ml.  Then, they were non-specifically 
immobilized to the polystyrene microtiter plate by direct adsorption.  After blocking with 
2% BSA, monoclonal mouse anti-porcine antibodies (10ug/mL) were incubated in each 
well, followed by rabbit anti-mouse IgG conjugated with alkaline phosphatase (AP) at a 
concentration of 0.5ug/mL.  PNPP was used as a substrate for the AP.  Each step was 
followed by a 1-hour incubation period at 37 degrees and automated washing in a 
microplate washer.  This is a compiled graph from different experiments.  As soon as each 
cytokine was bought, it was validated and the results are shown in the graph. 
16 
 
Porcine IL-6 gave the highest level of detection in the validation experiment; therefore, it 
was the first one to be tested.  The cytokine was added to normal porcine serum (not 
immunized with synthetic FMD protein) to be detected by mouse anti-porcine IL-6 added 
afterwards.  The unchallenged serum without added porcine IL-6 showed detection in the 
same range as the porcine IL-6 alone.  This shows that there was IL-6 present on the 
serum or that the antibodies used reacted with some other serum components.  The 
unchallenged serum with added IL-6 showed a high level of detection.  This result further 
validate that the mouse anti-porcine IL-6 was able to detect the IL-6 added. 
 
 
Figure 5. Binding of mouse anti-porcine IL-6 to normal porcine serum (S) with or without 
added porcine IL-6 measured by ELISA.  Procedure:  PBS was added to samples, which 
were then non-specifically immobilized to the polystyrene microtiter plate by direct 
adsorption.  After blocking with 2% BSA, monoclonal mouse anti-porcine IL-6 (10ug/mL) 
was incubated in each well, followed by rabbit anti-mouse IgG conjugated with alkaline 
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phosphatase (AP) at a concentration of 0.5ug/mL.  PNPP was used as a substrate for the 
AP.  Each step was followed by a 1-hour incubation period at 37 degrees and automated 
washing in a microplate washer.  Comparisons were made between wells to which no IL-6 
was added (blank), unsupplemented serum at a range of dilutions (S), IL-6 alone at a 
dilution of 1:80 (1.25ug/ml), and serum at these dilutions, to which IL-6 had been added at 
a concentration equivalent to that in the IL-6 alone wells. 
 
To test the specificity of the antibodies, four cytokines were spotted on a sensor chip for  
GSPRI.  Mouse anti-porcine IL-8 was passed across the sensor chip surface.  The data 
shows the highly specific interaction between the porcine IL-8 antigen and antibody pair.  
There was some non-specific interaction of the antibody and the BSA.   
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Figure 6.  Binding of mouse anti-porcine IL-8 to porcine IL-8 that was immobilized on a 
gold chip measured by GCSPR.  Procedure:  0.005% BSA in PBS was added to porcine 
IL-6, IL-8, IL-10, and IL-12, which were then non-specifically immobilized to the gold 
chip by direct adsorption.  After blocking with 2% BSA, a solution containing the anti-IL-
8 antibody was run at 100uL/min for 30minutes. A PBS flush followed the sample run.   
The anti-IL-8 was at a concentration of 20ug/mL.  The positive angle shifts show that 
there was specific binding of mouse anti-porcine IL-8. 
 
In order to further test the specificity of the antibodies, another experiment was set to test 
the mouse anti-porcine INFg.  Some non-specific substances such as albumin, BSA, and 
fish gel along with porcine INFg were spotted on a sensor chip.  Mouse anti-porcine INFg 
was run over the chip.  The data shows a high level of specificity between the porcine 
INFg and its antibody.  However, at the lowest INFg concentration (25ug/ml) the binding 
is comparable to the fish gel at 12.5ug/ml.   
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Figure 7.  Binding of mouse anti-porcine INFg to porcine INFg, BSA, albumin, and fish 
gel, immobilized on a gold chip measured by GCSPR.  Procedure:  PBS was added to 
porcine INFg, BSA, albumin, and fish gel, which were then non-specifically immobilized 
to the gold chip by direct adsorption.  After blocking with 2% BSA, a solution containing 
the anti-INFg antibody was run at 100uL/min for 30minutes. A PBS flush followed the 
sample run.  The positive angle shifts show that there was specific binding of mouse anti-
porcine INFg to its cognate antigen with some cross-reactivity to fish gel. 
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DISCUSSION 
 This project was developed under the hypothesis that a biological signature would 
allow distinction between vaccinated versus infected hosts with FMD.  Even though that 
could not yet be determined, some advancements have been accomplished.  One of the 
limitations encountered was the small amounts of critical regents that were available.  This 
restricted the experiments that could be done.  Cytokines are not usually used for coating 
the plate (as was done in the first ELISA experiments).  The standard procedure for 
detecting cytokines in serum is by using a sandwich arrangement with an antibody pair 
that recognizes different epitopes on the antigen.  This arrangement minimizes the amount 
of the cytokine used to obtain   detections in the range that the cytokines are present in 
serum. 
Another difficulty encountered was that the porcine antibodies were not 
sufficiently specific.  There was some cross reactivity between the secondary antibodies 
used to detect the mouse anti-porcine cytokines, and other experiment components such as 
BSA (data not shown).  When testing for the presence of porcine IL-2 in serum, the 
concentration of IL-2 encountered did not decrease proportionally with decreasing serum 
concentrations.  One of the possible explanations is that the goat anti-mouse IgG was 
detecting some serum component other than the primary antibody.  As a consequence, a 
concentration curve could not be developed.   
In established procedures, the laboratories that produce the reagents test them for 
cross-reactivity with the species used more frequently.  However, since this is a novel 
experiment, there are no standards to be followed.  Also, the possibility that when testing 
porcine or bovine sera on location there could be antibodies against other animals has to 
be contemplated when designing the sensor chip.  This problem did not happen in GCSPR 
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experiments since the secondary antibody is not used.  Therefore, the cross-reactivity is 
highly dependent on the type of assay used in the experiments.   
 The first component of this project was to validate the reagents using ELISA 
(Figure 4).  Then, serum from naïve and vaccinated pigs was tested for the presence of 
cytokines.  The presence of porcine IL-6 was detected in normal porcine serum with or 
without added porcine IL-6 by ELISA (Figure 5).  Furthermore, the presence of IL-8 was 
specifically detected when other cytokines were also spotted on the same sensor chip used 
in a grating-coupled surface plasmon resonance imaging system (Figure 6).   
 References with respect to the concentration of cytokines in porcine serum has 
being difficult to find.  However, according to the values presented in Table 1, we are still 
far from the desired detection range (assuming similar concentration of cytokines in pig).  
Our smallest detection is in the hundred nanogram per milliliter range.  Optimizing both 
sensitivity and specificity, and minimizing the potential for cross-reactivity between 
individual analytes can be accomplished by using the sandwich arrangement explained 
above. 
 The road for the completion of this project lies ahead.  However, the results 
obtained so far are very promising.  The maximization of the detection levels as well as 
the minimization of cross-reactivity while spotting more and more components of the 
signature on the sensor chip are the next steps to follow. 
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